Papillon-Lefèvre Syndrome

Bravo-Piris, J.; Aparicio, M.; Moran, M.; Armijo, M.

doi:10.1159/000249846

Cited by 21 publications

(1 citation statement)

References 10 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Increased susceptibility to infections is reported for approximately 20% of PLS cases. Most of these reports describe susceptibility to furunculosis, pyogenic infections of the skin, bronchitis, tonsillitis and pneumonia (Gorlin et al 1964, Haim & Munk 1965, Haneke et al 1975, Bravo‐Piris et al 1983, Bergman & Friedman‐Birnbaum 1988, Glenwright & Rock 1990, D'Angelo et al 1992, Oguzkurt et al 1996). Pyogenic liver abscesses for PLS patients has also been reported (Tosti et al 1988, Khandpur & Reddy 2001, Almuneef et al 2003).…”

Section: Discussionmentioning

confidence: 99%

Periodontal treatment of patients with Papillon–Lefèvre syndrome: a 3‐year follow‐up

Lundgren

Renvert

2004

J Clinic Periodontology

View full text Add to dashboard Cite

On five patients who were showing acceptable standard of oral hygiene and also compliance with the antibiotic medication, development of periodontitis on erupting teeth was prevented and disease activity on the previously periodontally involved teeth controlled during a 3-year period. Poor results of treatment were observed for three patients, all siblings. These patients failed to comply with the medication and also failed to improve their oral hygiene.

show abstract

Section: Discussionmentioning

confidence: 99%

Periodontal treatment of patients with Papillon–Lefèvre syndrome: a 3‐year follow‐up

Lundgren

Renvert

2004

J Clinic Periodontology

View full text Add to dashboard Cite

show abstract

Etretinate therapy in children with severe keratinization defects

Traupe

Happle

1985

Eur J Pediatr

View full text Add to dashboard Cite

Keratinization defects can be very severe and disfiguring diseases. The development of retinoids such as etretinate has provided us with an effective symptomatic form of oral therapy for these skin conditions. Based on our own experience, we briefly outline the therapeutic potential of etretinate in various keratinization defects (lamellar ichthyosis, Netherton syndrome, Sjögren-Larsson syndrome, mal de Meleda and juvenile pityriasis rubra pilaris). The toxicology of etretinate is reviewed with special regard to the treatment of children. Bone changes such as premature closure of the growth line or other unacceptable side-effects have so far not been observed. Guidelines for patient selection and for the safe treatment of children are given.

show abstract